10 drugs poised to be global best-sellers in 2030

Eli Lilly’s Mounjaro is projected to be the best-selling drug in the world in 2030, according to Statista data shared March 9 with Becker’s.

Statista is a global data company that provides market insights for 170 industries, including pharmaceuticals.

The company projects these 10 drugs will be the best-selling pharmaceutical products worldwide in 2030:

1. Mounjaro, a Type 2 diabetes medication

Manufacturer: Eli Lilly

Projected global sales in 2030: $36.2 billion

2. Skyrizi, a therapy for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis

Manufacturer: AbbVie

Projected global sales in 2030: $26.6 billion

3. Zepbound, a GLP-1 for obesity and sleep apnea

Manufacturer: Eli Lilly

Projected global sales in 2030: $25.5 billion

4. Dupixent, a therapy for nine chronic inflammatory conditions

Manufacturer: Sanofi/Regeneron

Projected global sales in 2030: $25.1 billion

5. Ozempic, a GLP-1 for Type 2 diabetes, cardiovascular disease and kidney disease

Manufacturer: Novo Nordisk

Projected global sales in 2030: $24.4 billion

6. Wegovy, a GLP-1 for obesity, cardiovascular disease and kidney disease

Manufacturer: Novo Nordisk

Projected global sales in 2030: $18.1 billion

7. Keytruda, a therapy for about a dozen cancers

Manufacturer: Merck

Projected global sales in 2030: $16.9 billion

8. Darzalex, a multiple myeloma therapy

Manufacturer: Johnson & Johnson/Genmab

Projected global sales in 2030: $16.6 billion

9. Biktarvy, an HIV-1 treatment

Manufacturer: Gilead

Projected global sales in 2030: $15.7 billion

10. CagriSema, an experimental GLP-1 drug for weight loss

Manufacturer: Novo Nordisk

Projected global sales in 2030: $15.2 billion